Mistletoe extract added to immunotherapy for advanced solid tumors
Part of Cancer, Immune system & allergy clinical trials.
This trial tests whether adding mistletoe extract (Iscador) to standard immunotherapy can make the treatment safer and boost the immune system's response against advanced solid tumors (excluding skin cancer). If you are already receiving or about to start a checkpoint inhibitor, this study may help understand if the combination works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor (like lung, breast, or colon) that has spread or cannot be removed by surgery – but not skin cancer.
- You are about to start or are already on a standard immunotherapy (checkpoint inhibitor) as part of your routine care.
- You have controlled brain metastases, take less than 10 mg of prednisolone (a steroid) daily, and have no known allergy to mistletoe.
- You are able to get up and move around or at least take care of yourself (ECOG 0-2).
- You are 18 or older and not under legal guardianship.
- You have never received mistletoe treatment before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (called MEDI5752) for people with certain solid tumors that have a special immune feature called 'mature tertiary lymphoid structures.' The drug is designed to help your immune system fight the cancer more effectively. You may be able to join even if you haven't had immunotherapy before, or if you had it and it stopped working after a while.
This trial tests adding ivermectin (a common anti-parasitic drug) to your current immunotherapy. The hope is that ivermectin may help the immunotherapy work better against your cancer.
This trial tests a combination of two investigational drugs (IMM2510 and IMM01) that work with your immune system to fight cancer. It may help people with advanced solid tumors who have not responded to other treatments.
This trial tests a new drug combination for people with advanced solid tumors. It aims to see if the combination is safe and may shrink tumors.
This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.
This trial is testing an experimental therapy (JCXH-211) that is injected directly into the tumor, combined with an immunotherapy drug (anti-PD-1 antibody). It is for people with advanced solid tumors who have not had success with standard treatments, and it aims to help the immune system fight the cancer more effectively.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.